Market Snapshot

Nasdaq ticker symbol:	IMNN
Stock price (04/28/2023):	$1.31
52-week range:	$1.06- $3.36
Market capitalization:	$12 million
Officer & Director ownership:	1.5%
Fiscal year-end:	12/31

Imunon, Inc. (Nasdaq: IMNN) is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform technologies: the **TheraPlas** modality for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and the **PlaCCine** modality for the development of nucleic acid vaccines for infectious diseases and cancer. These platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. Imunon will continue to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.

Investment Highlights

- **Leveraging innovative non-viral DNA with proprietary synthetic delivery system platforms and multiple potential indications** to create novel therapeutics with an initial clinical focus on **immuno-oncology and infectious diseases**. Imunon's TheraPlas technology delivers DNA therapeutics via synthetic, non-viral carriers, while PlaCCine is being developed to deliver plasmid DNA vaccines with a delivery system offering multiple benefits vs. currently available technologies.
- **Development of the PlaCCine modality in prophylactic vaccines, with strong evidence of immunogenicity and durability of protection** in a SARS-CoV-2 proof-of-concept model.
- **Later stage clinical trials offer opportunity for value-creating catalysts to address a multi-billion-dollar market** . OVATION 2 Phase 2 trial with IMNN-001(IL-12 immunotherapy) for the localized treatment of advanced ovarian cancer is fully enrolled. Earlier studies have shown strong efficacy signals; and interim Phase 2 data are promising with potential for a targeted therapy in BRCA-negative patients. GEN-1 has received FDA Fast Track & Orphan designations. A second Phase 2 trial has begun using IMNN-001 in combination with bevacizumab (Avastin®)
- **Focus on development of new modalities in cancer vaccines.**
- **Strong balance sheet** supports strategy into 2025 with a robust news flow of value-creating activities.
- **Highly experienced management team.** New CEO Dr. Corinne Le Goff, Pharm.D., MBA brings decades of global healthcare leadership experience across a range of therapeutic areas including oncology, vaccines and immunology and joins an existing talented team.

Our Disruptive Non-Viral DNA Technology Platform

Proprietary Synthetic Delivery and Facilitating System, that promote DNA Protection, Uptake, Bioavailability and Enhanced Antigen Expression

- **Gene Therapy Modality: TheraPlas**
  - Delivers DNA Plasmids Coding for Therapeutic Proteins
  - Multiple development programs on-going
- **Prophylactic Vaccine Modality: PlaCCine**
  - DNA Plasmid vectors engineered for next generation vaccine technology
  - Designed for multiple antigens with co-expression of immunomodulators
- **Tumor Associated Antigen Vaccine Modality: FixPlas**
  - Non-viral DNA vector encoding tumor associated antigens
  - Designed for multiple antigens with co-expression of immunomodulators
- **Neoepitope Personalized Cancer Vaccine Modality: IndiPlas**
  - Neoantigen Cancer Vaccine Approach: Revitalizing the Immune System
  - Targeting multiple epitopes selected for each individual patient



Pipeline of DNA-based Transformative Medicines

Modality	Program	Indication(s)	Discovery	IND enabling	Phase 1	Phase 2	Partnerships
TheraPlas	**IL-12 (OVATION)** Intraperitoneal (IP)	Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer	IMNN-001 (formerly GEN-1)				
TheraPlas	**IL-12** IP in combination with **bevacizumab**	Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer	IMNN-001 + bevacizumab				BREAK THROUGH CANCER #RadicalCollaboration
PlaCCine	**Multicistronic SARS-CoV-2**. Clinical Proof-of-Concept	COVID-19 Seasonal Vaccine	IMNN-101				
PlaCCine	**Prophylactic Vaccine**	Infectious Disease target	PL-X				THE WISTAR INSTITUTE
FixPlas	**Cancer Therapeutic Vaccine**	Trp2 Tumor Associated Antigen in Melanoma	IMNN-201				
IndiPlas	**Individualized Neoantigen Cancer Vaccines**		IP-Y				

IMNN-001: Lead Immuno-Oncology Program

IMNN-001 Targets the Tumor Microenvironment (TME) of Ovarian Cancer



Local Expression of IL-12 Favors Immune Modulation in Tumor Microenvironment

Phase 1/2 Open-Label Trial In Advanced Ovarian Cancer

- Enrollment completed
- 50% of expected primary endpoint data collected
- ITT population contains mix group of BRCA +/- subjects (BRCA + have much longer time to PFS due to PARPi)
- Primary Endpoint: PFS after 80 events or at least 16 months
- Secondary Endpoints: Clinical Response, Surgical Resection Score and Chemotherapy Response Score

Interim Data (50% of events)	NACT ONLY	NACT + GEN-1
Interval Debulking Surgery (n=70) R0 Resection Rate	56%	68%
Median Time to Progression (mos.) 50% of events	12.8	15.0
Chemotherapy Response Score of CRS3	17%	31%

PLACCINE Platform: Powering the Next Generation of Vaccines



Durability of Protection	Durable antigen expression induces robust immunological response
Breadth of Protection	Multicistronic vectors increase the breadth of immune response and allows for combination vaccines
Transmission Advantage	Strong T-cell activity. Option for co-expression of potent immune modifiers increases the immune response and lowers the risk of viral shedding
Safe and Convenient	Synthetic delivery systems present no risk of genotoxicity - no virus, or cytotoxicity - no device. Convenient handling for pandemic control.
Flexible Manufacturing	Truly versatile platform enables rapid response to changing pathogens. Stability and long shelf-life at normal refrigerator temperatures simplifies handling and distribution.

Near-Term Milestones

- **Report IMNN-001 OVATION 2 interim data – 2H23**
- **File IMNN-101 SARS-CoV-2 IND – 2H23**
- **Report IMNN-201vaccine candidate proof of concept data – 2H23**
- **Report IMNN-101 SARS-Co-V-2 Phase 1 results – 1H24**
- **Report IMNN-001 OVATION 2 topline results – 1H24**

Investor Relations Contacts

Imunon
Jeffrey W. Church, CFO
jchurch@imunon.com
(609) 896-9100
www.imunon.com

LHA
Kim Sutton Golodetz
kgolodetz@lhai.com
(212) 838-3777
www.lhai.com

The information contained herein was obtained from company and other sources believed to be reliable. This does not constitute the solicitation of the purchase or sale of securities. Except for historical information contained herein, matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. See recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. May 2023